文献リスト

1) Licht C, Weyersberg A, Heinen S, et al. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis. 2005; 45: 415-21

2) de Córdoba SR, de Jorge EG. Translational Mini-Review Series on Complement Factor H: Genetics and disease associations of human complement factor H. Clin Exp Immunol. 2008; 151: 1-13

3) 藤田禎三. I 因子欠損症. 日本臨牀. 2000; 別冊免疫症候群(下): 250-2

4) Kavanagh D, Richards A, Atkinson J. Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med. 2008; 59: 293-309

5) Cattaneo R. Four viruses, two bacteria, and one receptor: Membrane cofactor protein (CD46) as pathogens' magnet. J Virol. 2004; 78: 4385-8

6) Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005; 16: 1035- 50

7) Noris M, Remuzzi G. Non-Shiga toxin-associated hemolytic uremic syndrome. In: Zipfel P. editor. Complement and kidney disease. Basel: Brikhauser; 2006. p. 65-83

8) Kim Y, Miller K, Michael A. Breakdown products of C3 and factor B in hemolytic uremic syndrome. J Lab Clin Med. 1977; 89: 845-50

9) Barre P, Kaplan BS, de Chadarevian JP, et al. Hemolyric uremic syndrome with hypocomplementemia, serum C3Nef, and glomerular deposits of C3. Arch Pathol Lab Med. 1977; 101: 357-61

10) Hammar SP, Bloomer HA, McCloskey DA. Adult hemolyric uremic syndrome with renal arteriolar deposition of IgM and C3. Am J Clin Pathol. 1978; 70: 434-9

11) Warwicker P, Goodship TH, Donnel RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 1998; 53: 836-44

12) Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, et al. Gain of function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A. 2007; 104: 240-5

13) Fremeaux-Bacchi V, Regnier C, Blouin J, et al. Protective or aggressive: paradoxical role of C3 in atypical hemolytic uremic syndrome. Mol Immunol. 2007; 44: 172

14) Saunders RE, Abarrategui-Garrido C, Frémeaux-Bacchi V, et al. The interactive factor H-atypical hemolytic uremic syndrome mutation database and website: Update and integration of membrane cofactor protein and factor I mutations with structural models. Hum Mutat. 2007; 28: 222-34

15) Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C, et al. Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol. 2004; 15: 787-95

16) Rougier N, Kazatchkine MD, Rougier JP, et al. Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol. 1998; 9: 2318-26

17) Zipfel PF, Edey M, Heinen S, et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 2007; 16: e41

18) Monteferrante G, Brioschi S, Caprioli J, et al. Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. Mol Immunol. 2007; 44: 1704-8

19) Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005; 16: 555-63

20) Jozsi M, Licht C, Strobel S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood. 2008; 111: 1512-4

21) Józsi M, Strobel S, Dahse HM, et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood. 2007; 110: 1516-8

22) Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006; 108: 1267-79

23) Kavanagh D, Kemp EJ, Mayland E, et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005; 16: 2150-5

24) Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet. 2004; 41: e84

25) Richards A, Kemp EJ, Liszewski MK, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A. 2003; 100: 12966-71

26) Fremeaux-Bacchi V, Moulton EA, Kavanagh D, et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2006; 17: 2017-25

27) Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet. 2005; 14: 703-12

28) Richards A, Kathryn Liszewski M, Kavanagh D, et al. Implications of the initial mutations in membrane cofactor protein(MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol. 2007; 44: 111-22

29) Liszewski MK, Leung MK, Schraml B, et al. Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Mol Immunol. 2007; 44: 1559-68

30) Loirat C, Noris M, Fremeaux-Bacchi V, et al. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2008; 23: 1957-72

31) Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007; 18: 2392-400

32) Ariceta G, Besbas N, Johnson S, et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol. 2009; 24: 687-96

33) Davin JC, Olie KH, Verlaak R, et al. Complement factor H-associated atypical hemolytic uremic syndrome in monozygotic twins: concordant presentation, discordant response to treatment. Am J Kidney Dis. 2006; 47: e27-e30

34) Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol. 2003; 18: 1095-101

35) Miller RB, Burke BA, Schmidt WJ, et al. Recurrence of haemolytic-uremic syndrome in renal transplants: A single-centre report. Nephrol Dial Transplant. 1997; 12: 1425-30

36) Saland JM, Ruggenenti P, Remuzzi G, et al. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2009; 20: 940-9

37) Pickering MC, Warren J, Rose KL, et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci U S A. 2006; 103: 9649-54

38) Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004; 350: 552-9

39) Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008; 111: 1840-7

40) Kwon T, Dragon-Durey MA, Macher MA, et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant. 2008; 23: 2088-90

41) Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol. 2005; 16: 1392-403

42) Noris M, Remuzzi G. Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. Clin Exp Immunol. 2008; 151: 199-209

43) Benz K, Amann K. Pathological aspects of membranoproliferative glomerulonephritis (MPGN) and haemolytic uraemic syndrome (HUS) /thrombocytic thrombopenic purpura (TTP). Thromb Haemost. 2009; 101: 265-70

44) Jansen JH, Hogasen K, Grondahl AM. Porcine membranoproliferative glomerulonephritis type II: an autosomal recessive deficiency of factor H. Vet Rec. 1995; 137: 240-4

45) Hogasen K, Jansen JH, Mollnes TE, et al. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest. 1995; 9: 1054-61

46) Jansen JH, Hogasen K, Harboe M, et al. In situ complement activation in porcine membranoproliferative glomerulonephritis type II. Kidney Int. 1998; 53: 331-49

47) Pickering MC, Cook HT, Warren J, et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet. 2002; 31: 424-8

48) Pickering MC, Cook HT. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol. 2008; 151: 210-30

49) Meri S, Koistinen V, Miettinen A, et al. Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med. 1992; 175: 939-50

50) Licht C, Fremeaux-Bacchi V. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis. Thromb Haemost. 2009; 101: 271-8

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp